Differential Expression of Serum TUG1, LINC00657, miR-9, and miR-106a in Diabetic Patients With and Without Ischemic Stroke

Abstract

Background: Ischemic stroke is one of the serious complications of diabetes. Non-coding RNAs are established as promising biomarkers for diabetes and its complications. The present research investigated the expression profiles of serum TUG1, LINC00657, miR-9, and miR-106a in diabetic patients with and without stroke.Methods: A total of 75 diabetic patients without stroke, 77 patients with stroke, and 71 healthy controls were recruited in the current study. The serum expression levels of TUG1, LINC00657, miR-9, and miR-106a were assessed using quantitative real-time polymerase chain reaction assays.Results: We observed significant high expression levels of LINC00657 and miR-9 in the serum of diabetic patients without stroke compared to control participants. At the same time, we found marked increases of serum TUG1, LINC00657, and miR-9 and a marked decrease of serum miR-106a in diabetic patients who had stroke relative to those without stroke. Also, we revealed positive correlations between each of TUG1, LINC00657, and miR-9 and the National Institutes of Health Stroke Scale (NIHSS). However, there was a negative correlation between miR-106a and NIHSS. Finally, we demonstrated a negative correlation between LINC00657 and miR-106a in diabetic patients with stroke.Conclusion: Serum non-coding RNAs, TUG1, LINC00657, miR-9, and miR-106a displayed potential as novel molecular biomarkers for diabetes complicated with stroke, suggesting that they might be new therapeutic targets for the treatment of diabetic patients with stroke.

Taurine-Upregulated Gene 1 Attenuates Cerebral Angiogenesis following Ischemic Stroke in Rats

“…Previous studies have demonstrated that TUG1 plays an essential role in various ischemic stroke-related procedures [ 27 ]. They have also confirmed that the serum TUG1 level of diabetic patients with ischemic stroke is significantly higher than that of diabetic patients without ischemic stroke, and the serum TUG1 level is positively correlated with the NIHSS score of the patients [ 14 ]. TUG1 rs2240183 may be used as a new biomarker to predict the short-term prognosis of patients with ischemic stroke [ 28 ].…”

“…More recently, it was reported that TUG1 can regulate angiogenesis in diverse clinical scenarios [ 12 , 13 ]. Abdelaleem et al [ 14 ] found that serum lncRNA TUG1 might be a useful novel molecular biomarker for diabetes complicated by a stroke. Earlier researches suggested that TUG1 may have a vital role in the pathological changes after cerebral infarction [ 15 , 16 ].…”

Diabetes and diabetic associative diseases: An overview of epigenetic regulations of TUG1

“…Strong associations among TUG1, miR-9, LINC00657, and stroke severity were noted, with miR-106a showing a negative correlation. These non-coding RNAs could serve as potential indicators of disease and potential targets for treatment in diabetes stroke patients ( Abdelaleem et al, 2021 ). Diabetes mellitus is marked by β-cell loss and dysfunction, contributing to impaired insulin production and glucose regulation.…”

“…In recent years, the investigation of epigenetic mechanisms has unveiled novel layers of complexity in the origin and advancement of diverse conditions, among them diabetes and its linked complications, mechanisms have a significant role ( Abdelaleem et al, 2021 ). Diabetes mellitus, distinguished by persistent high blood sugar due to compromised insulin function or secretion, poses a worldwide health challenge with increasing occurrence ( Chen et al, 2021 , Bhat et al, 2023a , Bhat et al, 2023b , Bhat et al, 2023c ).…”

Circulating MicroRNAs and Extracellular Vesicle-Derived MicroRNAs as Predictors of Functional Recovery in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis

“…Figure 2.Forest plot for the correlation between the concentration of let-7i, miR-9, miR-21, miR-29b, miR-124, miR-124-3p, and NIHSS score; in certain cases, we address separately all reported studies (A) and (B) only studies with reported same miRNA source. References: miR-29b:[47,70,71,75]; let-7i:[54,56]; miR-9:[60,66,72,73]; miR-21:[68,69]; miR-124-3p:[61,63]; miR-124:[57,60,74].…”